Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Health

Disney

Duke Energy

Fiserv

PepsiCo

Philip Morris

PayPal

S&P Global

Vertex Pharmaceuticals

The fourth quarter 2022 earnings season continues to be subpar for the S&P 500.

10 Biggest Companies Reporting Earnings in the Second Week of Feb 2023

Johnson & Johnson

Coca-Cola

Procter & Gamble

According to the All-in-one Screener, a Premium feature of GuruFocus, five dividend kings stocks that have high guru ownership as of the third-quarter 2022 13F portfolio filings are Johnson & Johnson ( JNJ , Financial), Proctor & Gamble Co. ( PG , Financial), Coca-Cola Co. ( KO , Financial), AbbVie Inc. ( ABBV , Financial) and PepsiCo Inc. ( PEP , Financial).

5 Dividend King Stocks Gurus Are Feasting On

Amgen

AbbVie's two-decade Humira monopoly came to an end Tuesday after Amgen launched its biosimilar copy. But AbbVie stock was mostly unmoved.

AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff

U.S. patients will finally get access to cheaper versions of AbbVie Inc's blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.

AbbVie's Humira gets a U.S. rival, but costs could stay high

According to the financial report of Johnson & Johnson, a partner of AbbVie, sales of Imbruvica decreased in the 4th quarter of 2022 due to increased competition. In less than six months, Humira's biosimilars will go on sale in the United States.

AbbVie: Why The Company Is Still Overvalued

Chevron

Lowe's

UnitedHealth Group

Verizon

The recent rally in equities may be prying some cash off the sidelines. But if you're investing in pure growth stocks and avoiding dividend stocks altogether, I'd urge caution.

7 Dividend Stocks to Buy Now or You'll Be Kicking Yourself Later

Abbott Labs

Automatic Data Processing

Aflac

Cigna

Colgate-Palmolive

Clorox

Cisco Systems

Emerson Electric

Intel

Illinois Tool Works

Lockheed Martin

Medtronic

Microsoft

QUALCOMM

Rio Tinto plc Sponsored

AT&T

Walgreens

Waste Management

Walmart

We present the 2022 year-end review of our eight-year-old Passive DGI-Core Portfolio. We consider this portfolio and strategy as the foundation of our overall portfolio. We will provide updates on changes, additional investments, dividends collected, and an overall 2022 performance.

The 4% DGI Core Portfolio: 2022 Year-End Review

You can count on them for passive income and growth over time.

2 of the Best Dividend Stocks to Own in 2023

ABM Industries

Black Hills

Federal Realty Investment Trust

Gorman-Rupp

Leggett & Platt

Altria

National Fuel Gas

Northwest Natural Gas

Stanley Black & Decker

Sysco

Universal Corp

V.F.

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the Dow. The 47 Dividend Kings screened as of January 25, 2023, represented eight of eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 12.84%-36.92% topped-by ABM & NFG.

February Dividend Kings: 5 Buys; 1 To Watch

Fate Therapeutics

1Life Healthcare

Bio-Techne

Third Harmonic Bio Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

5 Cheapest Health Care Stocks You Should Think About

ATLANTA--( BUSINESS WIRE )--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2, 2023.

Alzamend Neuro to Present at Sequire Biotechnology Conference

CRISPR Therapeutics

Intellia Therapeutics

To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive.

3 Gene Editing Stocks to Buy Now OR You'll Be Kicking Yourself Later

IRVINE, Calif. , Jan. 25, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'.

Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023

The pharmaceutical specialist is facing a pivotal year in 2023, thanks to growing competition.

3 Reasons to Buy AbbVie and 2 Reasons Not to Buy

Target

Passive income is particularly welcome during tough market times.

Want Safety and Growth in 2023? Try These Dividend Stocks.

American States Water

Becton, Dickinson and Co.

Commerce Bancshares

Cincinnati Financial

California Water Service Group

Dover

Dividend Kings have an astounding track record of 50 or more years of higher dividend payouts. I rank the Dividend Kings using Quality Snapshots, a simple yet elegant system for assessing the quality of dividend growth stocks.

The Dividend Kings Ranked By Quality Score

News for AbbVie Stock (ABBV)